ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DVAX Dynavax Technologies Corp

11.76
-0.29 (-2.41%)
Mar 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,393,636
Bid Price 11.75
Ask Price 11.76
News -
Day High 12.0157

Low
9.475

52 Week Range

High
15.15

Day Low 11.65
Company Name Stock Ticker Symbol Market Type
Dynavax Technologies Corp DVAX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.29 -2.41% 11.76 19:32:36
Open Price Low Price High Price Close Price Prev Close
11.96 11.65 12.0157 11.70 12.05
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
19,525 2,393,636 $ 11.77 $ 28,162,992 - 9.475 - 15.15
Last Trade Time Type Quantity Stock Price Currency
18:40:20 5 $ 11.75 USD

Dynavax Technologies Corp Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.53B 130.61M - 232.28M -6.39M -0.05 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Dynavax Technologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DVAX Message Board. Create One! See More Posts on DVAX Message Board See More Message Board Posts

Historical DVAX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.0813.2611.6512.213,206,629-1.32-10.09%
1 Month12.3513.26511.6512.552,247,607-0.59-4.78%
3 Months13.9715.0111.6513.212,024,780-2.21-15.82%
6 Months13.7015.1511.6513.551,787,138-1.94-14.16%
1 Year9.5215.159.47513.181,651,6252.2423.53%
3 Years10.0321.397.0912.862,217,8341.7317.25%
5 Years7.9721.391.809.762,600,2593.7947.55%

Dynavax Technologies Description

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product.

Your Recent History

Delayed Upgrade Clock